Literature DB >> 12942458

Liver transplantation for primary sclerosing cholangitis in the Nordic countries: outcome after acceptance to the waiting list.

Bjørn Brandsaeter1, Ulrika Broomé, Helena Isoniemi, Styrbjörn Friman, Bent Hansen, Erik Schrumpf, Antti Oksanen, Bo-Göran Ericzon, Krister Höckerstedt, Heikki Mäkisalo, Rolf Olsson, Michael Olausson, Preben Kirkegaard, Kristian Bjøro.   

Abstract

Primary sclerosing cholangitis (PSC) is a common indication for liver transplantation, but evaluation of patients and timing of liver transplantation remain as major problems. Data from PSC and control patients listed for liver transplantation from 1990 through 2000 in the Nordic countries were recorded prospectively. Outcomes from the waiting list and after transplantation have been recorded for both groups. For PSC patients, regression analyses have been performed to analyze predictors of outcome. A total of 255 PSC and 610 control patients were accepted on the liver transplantation waiting list from 1990 to 2000. In the PSC group, 223 patients (87%) received a first liver allograft, and 32 patients (13%) died without transplantation. The corresponding figures for the control group were 89% and 10%. For PSC patients, the 5- and 10-year survival from the time of acceptance was 68% and 58%, respectively. A higher Model for End-Stage Liver Disease score and a shorter duration of PSC predicted death on the waiting list for PSC patients. PSC is a frequent indication for liver transplantation. In our material, serum bilirubin or Model for End-Stage Liver Disease score and PSC duration are predictors of outcome including survival of the waiting list.

Entities:  

Mesh:

Year:  2003        PMID: 12942458     DOI: 10.1053/jlts.2003.50169

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  10 in total

1.  Waitlist survival of patients with primary sclerosing cholangitis in the model for end-stage liver disease era.

Authors:  David Goldberg; Benjamin French; Arwin Thomasson; K Rajender Reddy; Scott D Halpern
Journal:  Liver Transpl       Date:  2011-11       Impact factor: 5.799

2.  [Autoimmune liver diseases].

Authors:  N Pannicke; C Schramm; A W Lohse
Journal:  Internist (Berl)       Date:  2012-08       Impact factor: 0.743

Review 3.  Primary sclerosing cholangitis: overview and update.

Authors:  Flavia Mendes; Keith D Lindor
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-10-12       Impact factor: 46.802

Review 4.  Current research on the treatment of primary sclerosing cholangitis.

Authors:  Ahmad H Ali; Elizabeth J Carey; Keith D Lindor
Journal:  Intractable Rare Dis Res       Date:  2015-02

5.  Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis.

Authors:  David S Goldberg; Amanda Camp; Alvaro Martinez-Camacho; Lisa Forman; Brett Fortune; K Rajender Reddy
Journal:  Liver Transpl       Date:  2013-03       Impact factor: 5.799

6.  Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis.

Authors:  James H Tabibian; Andrea Gossard; Mounif El-Youssef; John E Eaton; Jan Petz; Roberta Jorgensen; Felicity B Enders; Anilga Tabibian; Keith D Lindor
Journal:  Am J Ther       Date:  2017 Jan/Feb       Impact factor: 2.688

7.  Characterization of cultured cholangiocytes isolated from livers of patients with primary sclerosing cholangitis.

Authors:  James H Tabibian; Christy E Trussoni; Steven P O'Hara; Patrick L Splinter; Julie K Heimbach; Nicholas F LaRusso
Journal:  Lab Invest       Date:  2014-07-21       Impact factor: 5.662

Review 8.  Update on pharmacotherapies for cholestatic liver disease.

Authors:  Ahmad H Ali; James H Tabibian; Keith D Lindor
Journal:  Hepatol Commun       Date:  2016-12-21

9.  An Evaluation of the Usefulness of Extracorporeal Liver Support Techniques in Patients Hospitalized in the ICU for Severe Liver Dysfunction Secondary to Alcoholic Liver Disease.

Authors:  Mariusz Piechota; Anna Piechota
Journal:  Hepat Mon       Date:  2016-07-02       Impact factor: 0.660

10.  Outcome stagnation of liver transplantation for primary sclerosing cholangitis in the Model for End-Stage Liver Disease era.

Authors:  Johannes Klose; Michelle A Klose; Courtney Metz; Frank Lehner; Michael P Manns; Juergen Klempnauer; Nils Hoppe; Harald Schrem; Alexander Kaltenborn
Journal:  Langenbecks Arch Surg       Date:  2014-06-04       Impact factor: 3.445

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.